Gary J. Della'zanna

General Surgery
2001 Medical Pkwy
Annapolis, MD 21401

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications

Design and preliminary report of a randomized phase IIb clinical trial of multitargeted recombinant adenovirus 5 vaccines against CEA, MUC1, and brachyury (Tri-Ad5) and the IL-15 receptor superagonist nogapendekin alfa inbakicept in Lynch syndrome (TRIAD5-Plus): the first cross-network trial of the Cancer Prevention Clinical Trials Network (CP-CTNet).

Design and preliminary report of a randomized phase IIb clinical trial of multitargeted recombinant adenovirus 5 vaccines against CEA, MUC1, and brachyury (Tri-Ad5) and the IL-15 receptor superagonist nogapendekin alfa inbakicept in Lynch syndrome (TRIAD5-Plus): the first cross-network trial of the Cancer Prevention Clinical Trials Network (CP-CTNet).

Journal: Frontiers in immunology
Published: February 11, 2026

Effect of Aspirin on Biomarkers of Barrett's Esophagus After Successful Eradication with Radiofrequency Ablation.

Effect of Aspirin on Biomarkers of Barrett's Esophagus After Successful Eradication with Radiofrequency Ablation.

Journal: Digestive diseases and sciences
Published: October 22, 2024

Evaluating Intermittent Dosing of Aspirin for Colorectal Cancer Chemoprevention.

Evaluating Intermittent Dosing of Aspirin for Colorectal Cancer Chemoprevention.

Journal: Cancer prevention research (Philadelphia, Pa.)
Published: April 06, 2024

Epidermal Growth Factor Receptor Inhibition With Erlotinib in Liver: Dose De-Escalation Pilot Trial as an Initial Step in a Chemoprevention Strategy.

Epidermal Growth Factor Receptor Inhibition With Erlotinib in Liver: Dose De-Escalation Pilot Trial as an Initial Step in a Chemoprevention Strategy.

Journal: Gastro hep advances
Published: June 02, 2023

Phase II trial of weekly erlotinib dosing to reduce duodenal polyp burden associated with familial adenomatous polyposis.

Phase II trial of weekly erlotinib dosing to reduce duodenal polyp burden associated with familial adenomatous polyposis.

Journal: Gut
Published: November 10, 2021

Phase I double-blind, placebo-controlled trial of dolcanatide (SP-333) 27 mg to explore colorectal bioactivity in healthy volunteers.

Phase I double-blind, placebo-controlled trial of dolcanatide (SP-333) 27 mg to explore colorectal bioactivity in healthy volunteers.

Journal: Cancer biology & therapy
Published: October 11, 2021

Randomized Phase II Trial of Polyphenon E versus Placebo in Patients at High Risk of Recurrent Colonic Neoplasia.

Randomized Phase II Trial of Polyphenon E versus Placebo in Patients at High Risk of Recurrent Colonic Neoplasia.

Journal: Cancer prevention research (Philadelphia, Pa.)
Published: November 20, 2020

Efficacy of Difluoromethylornithine and Aspirin for Treatment of Adenomas and Aberrant Crypt Foci in Patients with Prior Advanced Colorectal Neoplasms.

Efficacy of Difluoromethylornithine and Aspirin for Treatment of Adenomas and Aberrant Crypt Foci in Patients with Prior Advanced Colorectal Neoplasms.

Journal: Cancer prevention research (Philadelphia, Pa.)
Published: March 27, 2019

Bioactivity of Oral Linaclotide in Human Colorectum for Cancer Chemoprevention.

Bioactivity of Oral Linaclotide in Human Colorectum for Cancer Chemoprevention.

Journal: Cancer prevention research (Philadelphia, Pa.)
Published: November 10, 2016

Clinical Study of Ursodeoxycholic Acid in Barrett's Esophagus Patients.

Clinical Study of Ursodeoxycholic Acid in Barrett's Esophagus Patients.

Journal: Cancer prevention research (Philadelphia, Pa.)
Published: July 08, 2015

Spectral biomarkers for chemoprevention of colonic neoplasia: a placebo-controlled double-blinded trial with aspirin.

Spectral biomarkers for chemoprevention of colonic neoplasia: a placebo-controlled double-blinded trial with aspirin.

Journal: Gut
Published: May 15, 2015

A combination of esomeprazole and aspirin reduces tissue concentrations of prostaglandin E(2) in patients with Barrett's esophagus.

A combination of esomeprazole and aspirin reduces tissue concentrations of prostaglandin E(2) in patients with Barrett's esophagus.

Journal: Gastroenterology
Published: October 24, 2011
Showing 1-12 of 12

Last Updated: 09/26/2026